Induction chemoradiation and surgical resection for non–small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)

Rusch, Valerie W.; Giroux, Dorothy J.; Kraut, Michael; Crowley, John; Hazuka, Mark B.; Johnson, David H.; Goldberg, Melvyn; Detterbeck, Frank C.; Shepherd, Frances A.; Burkes, Ronald L.; Winton, Timothy; Deschamps, Claude; Livingston, Robert B.; Gandara, David R.

doi:10.1067/mtc.2001.112465

Cited by 264 publications

(174 citation statements)

References 35 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…However, the compliance rate for this strategy was reported to be poor (Pisters et al, 2000;Rusch et al, 2001). In addition, some deaths related to drug toxicity have also been reported during the consolidation phase (Albain et al, 2005), prompting further questioning of its benefits.…”

Section: Toxicity Of the Chemoradiotherapymentioning

confidence: 99%

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

Kunitoh¹,

Suzuki²

2007

Br J Cancer

View full text Add to dashboard Cite

The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.

show abstract

Section: Toxicity Of the Chemoradiotherapymentioning

confidence: 99%

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

Kunitoh¹,

Suzuki²

2007

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The Japan Clinical Oncology Group (JCOG) protocol 9806 is similar to the North American intergroup effort (Table 1) [38][39][40].…”

Section: Concurrent Chemotherapy and Radiation Followed By Surgerymentioning

confidence: 99%

“…Of the patients who completed induction therapy and went on to surgery, the 2-year survival rates were 55% for all patients and 70% for those who underwent complete resection [38,39]. Updated results noted a 33-month median survival and a 5-year overall survival rate of 41% for the total cohort [39].The Japan Clinical Oncology Group (JCOG) protocol 9806 is similar to the North American intergroup effort (Table 1) [38][39][40].Wright et al[41] from the Massachusetts General Hospital published a retrospective review of patients treated with different institutional protocols consisting of preoperative chemoradiation and radiation alone. The patients who received chemotherapy had a higher complete resection rate, higher pathologic complete response rate, lower local recurrence rate, and longer survival than patients treated with radiation alone.…”

mentioning

confidence: 99%

“…Sixty-six percent of those who went on to surgery had pathologic complete responses (36%) or minimal microscopic disease (30%) on resection. Of the patients who completed induction therapy and went on to surgery, the 2-year survival rates were 55% for all patients and 70% for those who underwent complete resection [38,39]. Updated results noted a 33-month median survival and a 5-year overall survival rate of 41% for the total cohort [39].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Superior Sulcus Tumors: A Mini-Review

Archie¹,

Thomas

2004

The Oncologist

View full text Add to dashboard Cite

The management and outcome for superior sulcus tumors have remained unchanged for 40 years. The rarity of these tumors has led to varying treatment techniques spanning decades, from which no solid conclusions can be drawn. Recent advances in combined-modality therapy have offered the first inkling that a paradigm shift is on the horizon. Here, we review the history and new advances in treating this challenging pulmonary neoplasm. The Oncologist 2004;9:550-555 The Oncologist 2004;9:550-555 www.TheOncologist.com Antonio, 7703 Floyd Curl Dr., San Antonio, Texas 78229, USA. Telephone: 210-616-5684; Fax: 210-949-5085; e-mail: cthomas@ctrc.net; Website: http://www.uthscsa.edu/radiationoncology Received January 27, 2004; accepted for publication May 10, 2004. ©AlphaMed Press 1083-7159/2004 In 1924, Pancoast [1] reported the clinical and radiographic findings associated with superior sulcus tumors. He initially thought that these tumors arose from epithelial rest cells from the fifth brachial cleft. Eight years later, Tobias [2] and Pancoast [3] simultaneously, correctly recognized that bronchogenic carcinoma was the primary cause of this syndrome. Correspondence: Charles R. Thomas Jr., M.D., Department of Radiation Oncology, University of Texas Health Science Center at San HISTORYSuperior sulcus tumors usually arise in the apex of the lung and may invade the second and third ribs, the brachial plexus, the subclavian vessels, the stellate ganglion, and adjacent vertebral bodies [4]. Pancoast syndrome is characterized by pain, which may arise in the shoulder or chest wall or radiate to the neck. Pain characteristically radiates to the ulnar surface of the hand. Horner's syndrome, which is composed of ptosis, meiosis, and anhydrosis, results from invasion of the paravertebral sympathetic chain. Weakness and atrophy of the hand and parasthesias are a common clinical finding resulting from invasion into the C8 and T1 roots of the brachial plexus. More infrequent manifestations include supraclavicular adenopathy, superior vena cava syndrome, and involvement of the phrenic or laryngeal nerves [5].Prior to the 1950s, superior sulcus tumors were uniformly fatal. Chardack and MacCallum [6] reported the The Oncologist ® Lung Cancer LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe the diagnostic work-up for superior sulcus (Pancoast) tumors of the lung.2. List the major prognostic factors pertaining to outcome in patients with superior sulcus (Pancoast) tumors.3. Discuss the recent (SWOG 94-16) and current (SWOG-0220) intergroup trials for superior sulcus (Pancoast) tumors.Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME by guest on May 9, 2018 http://theoncologist.alphamedpress.org/ Downloaded fromThis material is protected by U.S. Copyright law.Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com first successful treatment with resection followed by postoperative radiation...

show abstract

“…In small cell lung cancer, radiotherapy is performed after chemotherapy (adjuvant) in tumors staged as extensive disease, 1 and concomitantly in tumors staged as localized disease. 2 In non-small cell lung cancer, radiotherapy is indicated before or after surgery (adjuvant), with the purpose of making them surgically resectable or to prevent relapse of locoregional disease and tumors with positive margins, 3,4 while in unresectable tumors, it is preferably associated with chemotherapy. 5 Radiation therapy has progressed in recent decades due to advances in computerized systems that allow the recognition of internal structures in the body.…”

Section: Introductionmentioning

confidence: 99%